What do Ovarian Cancer Patients expect from treatment? https://tinyurl.com/mr3rbbxy Increasingly medicine is being consumer driven. There is now an expectation that any course of treatment should actively involve the patient. However , this is not always the case and this survey of women with ovarian cancer shows their expec t ations and hopes about treatment and how the reality is different. Using an on-line platform, (Patients Like Me) 30 women with ovarian cancer received a questionnaire seeking to determine their hopes and expectations at the beginning of their treatment and the actual experience of the process. In addition, information was sought about the impact of this experience on their quality of life. Results from the survey showed little understanding about the nature of the disease and the side effects of treatment. Most women initially had a realistic expectation of complete cure . Only 20% of women thought they were completely cured after the first course of t...

Cognitive and brain health in women with early bilateral salpingo -oophorectomy: Implications for risk, resilience, and subjective cognitive decline https://tinyurl.com/mwayffrf Dementia and cognitive decline are twice as likely for women. It seems that oestrogen i s neuro -protective and premature menopause which occurs after removal of fallopian tubes and ovaries a ccelerates this process . It has been well known that dementia in the elderly has been associated with this surgical procedure. Th is article looks at younger women and measures the impact on their neurological status after surgery before the age of 49 by comparing the outcomes with age-matched controls and a group of BRCA positive women. Standard testing for cognitive decline includes short-term memory tests , logical thought and depression. All participants had MRI brain imaging looking for decrease in brain volumes . Results from the retrospective study show ed loss of cognitive function for women who had earl...

BRCA1 promoter methylation predicts PARPi response in ovarian cancer: insights from the KOMET study https://tinyurl.com/556t49sr For ovarian cancer patients who carry the BRCA mutation , the use of PARP inhibit ion ( PARPi ) has significantly improved survival. It has been noted that some women without the BRCA mutation benefit from PARPi . This has led to a push for PARPi treatment for all. However, the cost and side effects of PARPi precludes this. As an attempt to determine which patients benefit from PARPi , additional genomic testing known as h omologous recombination deficiency (HRD) analysis shows genomic instability. Use of this has shown that up to half of the women with ovarian cancer will benefi t from PARP i. HRD analysis is expensive and may be inconclusive, meaning that it’s use is restricted. In addition, some women who might benefit from PARPi do not have the typical chromosomal mutation which causes HRD but rather have an epigenetic change called ...

Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities https://tinyurl.com/4698cc7c In the treatment of ovarian cancer, the most important determinant of survival is the effectiveness of the initial surgical procedure. The aim is complete clearance and for about 80% of women no residual cancer can be detected either by CT scan or plasma CA 125 levels. Despite this only about 20% of women will have be en cured sugge sting that residual cancer is present despite evidence to the contrary. This study shows the true rate of minimal residual disease (MRD) , by measuring c i rculatin g tumour DNA (CT DNA) , and by repeat “second look” laparoscopy after completion of surgery and chemo. Findings from the study showed that of 95 patients thought to have had a complete clearance at initial surgery almost half had MRD with abnormal CT DNA or second look laparoscopy. These women had ...